ArticleOphthalmology2026
The Association between Glaucoma and Dementia in a National Cohort of All of Us Participants.
Article in Ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ocular Glymphatic System: Its Modulation and Role in Intraocular Tumors.Investigative ophthalmology & visual science · 2026Review
- Increased risk of incident dementia associated with vitamin D deficiency in glaucoma patients: a TriNetX cohort study.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo assess the association between glaucoma and its subtypes and incidence of dementia and its subtypes across APOE genotypes in the National Institutes of Health (NIH) All of Us Research Program.
designRetrospective, longitudinal cohort study.
participantsA cohort of individuals with linked electronic health record (EHR) data in the All of Us dataset, with every individual with a glaucoma diagnosis matched with four control participants. Participants diagnosed with dementia before glaucoma were excluded.
methodsA 1:4 cohort of participants with glaucoma and control participants was created using a propensity score-matching design that considered age, race, ethnicity, and sex. Participants with whole-genome sequencing data were stratified by APOE genotype for sub-analyses. A multivariable Cox regression model was used to adjust for residual imbalance in comorbidities.
main outcome measuresIncidence of dementia and its subtypes.
resultsAmong the 393 497 All of Us participants with linked EHRs, we identified 9444 individuals (2.40%) with glaucoma diagnoses (excluding participants with diagnoses of dementia before glaucoma) and 37 776 matched controls without glaucoma. During the observation period (median, 6.5 years; interquartile range, 3.3-10.7 years), dementia was diagnosed in 1127 individuals (2.39%). Glaucoma was associated with a significantly increased risk of all-cause dementia (adjusted hazard ratio [aHR], 1.23; 95% confidence interval [CI], 1.08-1.40), Alzheimer's disease (aHR, 1.60; 95% CI, 1.26-2.02), and vascular dementia (aHR, 1.38; 95% CI, 1.04-1.83). Among glaucoma subtypes, primary open-angle glaucoma (POAG, N = 5756) and normal-tension glaucoma (NTG, N = 1106) were linked to an elevated risk of Alzheimer's disease (POAG: aHR, 1.48, 95% CI, 1.11-1.96; NTG: aHR, 1.87, 95% CI, 1.09-3.18), whereas angle-closure glaucoma (N = 3150) showed no significant association (aHR, 1.49; 95% CI, 0.91-2.27). Glaucoma was associated with an increased risk of all-cause dementia across the three APOE genotypes assessed, (ε2ε3 > ε3ε3 > ε3ε4).
conclusionsGlaucoma was associated with a higher risk of dementia across APOE genotypes, with varying associations among glaucoma and dementia subtypes. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.